Success Story: EB-1A Approved Despite NOID! We Helped an Iranian Postdoctoral Scholar Achieve Victory
Client’s Testimonial:
“I sincerely appreciate the expertise of the Chen Immigration team in preparing my case and handling the response.”
On April 10th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Scholar in the Field of Medical Research (Approval Notice).
General Field: Medical Research
Position at the Time of Case Filing: Postdoctoral Scholar
Country of Origin: Iran
State of Residence at the Time of Filing: Illinois
Approval Notice Date: April 10th, 2025
Processing Time: 2 months, 3 days (Premium Processing Requested)
Case Summary:
At North America Immigration Law Group, we are proud to share the success of an EB1A (Alien of Extraordinary Ability) petition for an MD holder. Filed under Premium Processing, the petition received a Notice of Intent to Deny (NOID) but was ultimately approved thanks to our robust legal response and the client’s outstanding qualifications.
Our client, an expert in the field of internal medicine and cardiology, is known for his groundbreaking work on non-invasive biomarkers, machine learning-based risk prediction models, and epidemiological studies of cardiovascular disease (CVD). He is currently employed at a top-tier research institution in the U.S., where he focuses on improving diagnostic tools and treatment strategies for CVD patients.
To support the petition under the EB1A framework, we highlighted:
Publications and Citations: He has authored 93 peer-reviewed articles, including 33 first-/co-first-authored, with a total of 1,093 citations and an h-index of 13, placing him among the top 4% of medical researchers.
Peer Review Contributions: He has conducted 494 peer reviews for prestigious journals, and he serves on editorial boards of several international journals.
Significance and Impact: His work has informed critical research on cardiovascular risk stratification, heart failure, sleep apnea, environmental health, and health disparities. His models and findings are cited by scholars in over 60 countries and have been applied globally across both academic and clinical settings.
The petition was further reinforced by 4 recommendation letters from independent experts. These letters attested to the client’s contributions of major significance and international acclaim. One recommender noted:
“Considering the value of machine learning models in predicting adverse cardiovascular outcomes and assessing the efficacy of aortic valve replacement surgery across populations, [Client’s] research presents valuable benefits to personalized medicine and the embedding of medicine with technology. It is, therefore, within the interests of the United States to allow [Client’s] research to continue.”
We are honored to have supported this remarkable physician-scientist and thrilled to witness his recognition as a top-tier contributor to U.S. medical research through this well-deserved EB1A approval.